Industry

Clinically tested probiotics for common colds management designed by SynBalance

A new scientific publication on the beneficial effect of probiotics on cold symptoms relief, immune response enhancement, and quality of life in healthy adults during winter seasons.

Microbiome therapeutics take a bold step into ALS: MaaT Pharma’s MaaT033 shows promise in Phase 1b study

MaaT Pharma’s venture marks an innovative and hopeful chapter in the ongoing effort to fight neurodegeneration.

Probiotics on Amazon: five-country analysis highlights key market differences

Access the full report on Europe's probiotic market trends on Amazon, with comprehensive data on search volumes, keyword strategies, pricing analysis and market penetration.

The microbiome isn’t a trend. It’s the health OS we’ve been missing

Is the microbiome just a trend or the future of health? Welcome to the first article of the Bold Column.

MaaT Pharma set to showcase groundbreaking preclinical results in cancer immunotherapy

Preclinical findings will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago.

Inner Brightness’s Akkermansia muciniphila: a breakthrough in the gut health market

This pioneering three-in-one formula uniquely combines pasteurized Akkermansia muciniphila AKK PROBIO, DigeSEB® broad-spectrum digestive enzymes, and B-Complex vitamins.

Lallemand Health Solutions launches Cerenity, a clinically studied probiotic formula to support healthy aging

Cerenity™ improves mobility, strength, and muscle function in older adults by modulating the gut-muscle axis.

NIST redefines gut microbiome research with breakthrough reference material

The Human Gut Microbiome Reference Material (RM) promises to standardize and enhance research efforts in a field poised to transform healthcare.

MaaT013 cleared for pediatric trials: EMA approval marks key milestone for microbiome therapy in aGvHD

MaaT013, a Microbiome Ecosystem Therapy™ (MET), is designed to restore the gut microbiome in pediatric patients aged 6 to 18 years with steroid-resistant aGvHD.

Bloom Science’s Live Biotherapeutic BL-001 achieves significant weight loss in Phase 1 trial

Positive results from Phase 1 trial of BL-001, an innovative live biotherapeutic product (LBP) designed to replicate the metabolic effects of the ketogenic diet.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top